S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Forecast, Price & News

$144.55
-0.71 (-0.49%)
(As of 05/26/2023 ET)
Compare
Today's Range
$144.55
$144.58
50-Day Range
$133.12
$153.10
52-Week Range
$104.50
$153.10
Volume
649 shs
Average Volume
3,719 shs
Market Capitalization
N/A
P/E Ratio
177.14
Dividend Yield
1.94%
Price Target
N/A

AstraZeneca MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.25mentions of AstraZeneca in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.05 out of 5 stars


AZNCF stock logo

About AstraZeneca (OTCMKTS:AZNCF) Stock

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZNCF Stock News Headlines

"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
What Does AstraZeneca's Debt Look Like?
See More Headlines
Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Pharmaceuticals: Major
Sub-Industry
N/A
Current Symbol
OTCMKTS:AZNCF
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Pascal Soriot
    Chief Executive Officer & Executive Director
  • Pam P. Cheng
    Executive VP-Operations & Information Technology
  • Aradhana Sarin
    Chief Financial Officer & Executive Director
  • Menelas NICOLAS Pangalos
    EVP-Biopharmaceuticals Research & Development
  • Cindy L. Hoots
    Chief Digital & Information Officer













AZNCF Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZNCF shares.
View AZNCF analyst ratings
or view top-rated stocks.

How have AZNCF shares performed in 2023?

AstraZeneca's stock was trading at $139.28 at the start of the year. Since then, AZNCF stock has increased by 3.8% and is now trading at $144.55.
View the best growth stocks for 2023 here
.

Are investors shorting AstraZeneca?

AstraZeneca saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 502,800 shares, a drop of 9.5% from the April 15th total of 555,700 shares. Based on an average daily volume of 21,500 shares, the short-interest ratio is presently 23.4 days.
View AstraZeneca's Short Interest
.

Is AstraZeneca a good dividend stock?

AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

What is AstraZeneca's stock symbol?

AstraZeneca trades on the OTCMKTS under the ticker symbol "AZNCF."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a number of retail and institutional investors. Top institutional investors include Boston Common Asset Management LLC (0.00%) and Vigilant Capital Management LLC (0.00%).

How do I buy shares of AstraZeneca?

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZNCF stock can currently be purchased for approximately $144.55.

How can I contact AstraZeneca?

The company can be reached via phone at 442037495000.

This page (OTCMKTS:AZNCF) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -